SCHEMBL17768596

SCHEMBL17768596

CC(=O)OC1Cc2cccnc2C1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PTAFR P25105 2/20 0.35
GABRA1 P14867 2/20 0.35
GABRB2 P47870 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
S100A4 P26447 2/20 0.34
TDP2 O95551 1/20 0.33
NSD2 O96028 1/20 0.33
ABL1 P00519 1/20 0.33
PLCG1 P19174 1/20 0.33
CES1 P23141 1/20 0.33
PAX8 Q06710 1/20 0.33
RIN1 Q13671 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17768605 0.79 GABRA1 (0.34) KDM4EMEN1KMT2APTAFRGABRA1
SCHEMBL17768604 0.79 GABRA1 (0.34) KDM4EMEN1KMT2APTAFRGABRA1
SCHEMBL8605029 0.76 ACHE (0.51) KDM4EMEN1KMT2AMAPTL3MBTL1
SCHEMBL943506 0.76 ACHE (0.51) KDM4EMEN1KMT2AMAPTL3MBTL1
SCHEMBL10270851 0.74 ACHE (0.52) KDM4EMEN1KMT2AMAPTL3MBTL1
SCHEMBL19899123 0.73 NOS3 (0.38) ALDH1A1HPGDPOLB
SCHEMBL19899151 0.73 KIF11 (0.39) GABRA1GABRB2TDP1NSD2
SCHEMBL883069 0.71 MAPT (0.56) KDM4EMEN1KMT2AMAPTL3MBTL1
SCHEMBL2147611 0.71 CHRM4 (0.41) FNTAFNTB
SCHEMBL11490469 0.70 POLB (0.50) GABRA1GABRB2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10472347-B2 Aminopyrazine compounds with A2A antagonist properties MERCK SHARP & DOHME CORP. (US) 2019-11-12 US disclosed
US-10472347-B2 Aminopyrazine compounds with A2A antagonist properties MERCK SHARP & DOHME CORP. (US) 2019-11-12 US disclosed
US-20180327385-A1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2018-11-15 US disclosed
EP-3220910-A1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES Merck Sharp & Dohme Corp. (US) 2017-09-27 EP disclosed
WO-2016081290-A1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2016-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10472347-B2 Aminopyrazine compounds with A2A antagonist properties ADORA2A, ADORA1, ADORA3 KDM4E 3600/4885MEN1 2777/4885KMT2A 1004/4885
US-20180327385-A1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES ADORA2A, ADORA1, ADORA3 KDM4E 3600/4885MEN1 2777/4885KMT2A 1004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.